Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

Bandelow, Borwin, Zohar, Josef, Hollander, Eric, Kasper, Siegfried, Möller, Hans-Jürgen, WFSBP Task Force on Treatment Guide·2002·The World Journal of Biological Psychiatry

Abstract

In this report, recommendations for the pharmacological treatment of anxiety and obsessive-compulsive disorders are presented, based on available randomized, placebo- or comparator-controlled clinical studies. Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for panic disorder. Tri2-cyclic antidepressants (TCAs) are equally effective, but they are less well tolerated than the SSRIs. In treatment-resistant cases, benzodiazepines like alprazolam may be used when the patient does not have a history of dependency and tolerance. Due to possible serious side effects and interactions with other drugs and food components, the irreversible monamine oxidase inhibitor (MAOI) phenelzine should be used only when first-line drugs have failed. In generalised anxiety disorder, venlafaxine and SSRIs can be recommended, while buspirone and imipramine may be alternatives. For social phobia, SSRIs are recommended for the first line, and MAOIs, moclobemide and benzodiazepines as second line. Obsessive-compulsive disorder is best treated with SSRIs or clomipramine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/15622970209150621

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 316

  1. AACAP, 1998, J Am Acad Child Adolesc Psychiatry, 37, 27S, 10.1097/00004583-199810001-00003 · DOI · Paper page
  2. Agid O, 1999, J Clin Psychiatry, 60, 55, 10.4088/JCP.v60n0112d · DOI
  3. Allgulander C, 1999, Acta Psychiatr Scand, 100, 193, 10.1111/j.1600-0447.1999.tb10845.x · DOI
  4. Altamura A C., 1999, Int Clin Psychopharmacol, 14, 239, 10.1097/00004850-199907000-00006 · DOI
  5. Altshuler L L., 2001, Postgrad Med, 1
  6. Amore M, 1999, Hum Psychopharmacol Clin Exp, 14, 429, 10.1002/(SICI)1099-1077(199908)14:6<429::AID-HUP108>3.0.CO;2-3 · DOI
  7. Amore M, 1999, Hum Psychopharmacol Clin Exp, 14, 435, 10.1002/(SICI)1099-1077(199908)14:6<435::AID-HUP109>3.0.CO;2-B · doi:10.1002/(sici)1099-1077(199908)14:6<435::aid-hup109>3.0.co;2-b
  8. Andersch S, 1991, Acta Psychiatr Scand Suppl, 365, 18, 10.1111/j.1600-0447.1991.tb03097.x · DOI
  9. Ansseau M, 1991, Psychopharmacology, 104, 439, 10.1007/BF02245646 · DOI
  10. APA, 1994, American Psychiatric Association. Diagnostic and Statistical Manual of Mental DisordersFourth Edition
  11. APA, 1998, Am J Psychiatry, 155, 1, 10.1176/ajp.155.1.1 · DOI · Paper page
  12. Atmaca M, 2002, Int Clin Psychopharmacol, 17, 115, 10.1097/00004850-200205000-00004 · DOI
  13. Austin M PV, 1998, Med J Aust, 169, 428, 10.5694/j.1326-5377.1998.tb126837.x · DOI
  14. Bakish D, 1996, Psychopharmacol Bull, 32, 135
  15. Bakker A, 1999, J Clin Psychiatry, 60, 831, 10.4088/JCP.v60n1205 · DOI
  16. Baldwin D, 1999, Br J Psychiatry, 175, 120, 10.1192/bjp.175.2.120 · DOI · Paper page
  17. Ballenger J C, 1999, Biol Psychiatry, 46, 1579, 10.1016/S0006-3223(99)00220-6 · DOI
  18. Ballenger J C., 1998, J Clin Psychiatry, 59, 47, 10.4088/JCP.v59n0201 · DOI
  19. Ballenger J C., 1998, J Clin Psychiatry, 59, 54
  20. Ballenger J C., 1998, Am J Psychiatry, 155, 36, 10.1176/ajp.155.1.36 · DOI · Paper page
  21. Ballenger J C., 2000, J Clin Psychiatry, 61, 60
  22. Ballenger J C., 2001, J Clin Psychiatry, 62, 53
  23. Bandelow B, 1995, Eur Arch Psychiatry Clin Neurosci, 245, 165, 10.1007/BF02193090 · DOI
  24. Bandelow B, 1999, Hogrefe & Huber PublishersPanic and Agoraphobia Scale (PAS)
  25. Bandelow B, 2002, J Handbook on Depression and Anxiety
  26. Barlow D H, 1997, J Clin Psychiatry, 58, 32, 10.4088/JCP.v58n0106e · DOI
  27. Barlow D, 1989, Behav Ther, 20, 261, 10.1016/S0005-7894(89)80073-5 · DOI · Paper page
  28. Beauclair L, 1994, J Clin Psychopharmacol, 14, 111, 10.1097/00004714-199404000-00005 · DOI
  29. Beck A T., 1985, Anxiety disorders and phobias—a cognitive perspective
  30. Beck A T., 1992, Am J Psychiatry, 149, 778, 10.1176/ajp.149.6.778 · DOI · Paper page
  31. Benjamin J, 1995, Am J Psychiatry, 152, 1084, 10.1176/ajp.152.7.1084 · DOI · Paper page
  32. Benjamin J, 2000, Psychopharmacology (Berl), 149, 194, 10.1007/s002130000372 · DOI
  33. Bezchlibnyk‐Butler K Z., 2001, Clinical handbook of psychotropic drugs
  34. Bisserbe J, 1997, Eur Psychiatry, 12, 82, 10.1016/S0924-9338(97)89646-0 · DOI
  35. 10.1001/archpsyc.1993.01820130046008 · DOI · Paper page
  36. Blier P, 1996, Int Clin Psychopharmacol, 11, 37, 10.1097/00004850-199603000-00005 · DOI
  37. 10.1192/bjp.179.1.23 · DOI · Paper page
  38. Bogetto F, 2000, Psychiatry Res, 96, 91, 10.1016/S0165-1781(00)00203-1 · DOI
  39. Borkovec T D., 1996, Long‐term treatment for the anxiety disorders, 171
  40. Bouwer C, 1998, J Affect Disord, 49, 79, 10.1016/S0165-0327(97)00182-1 · DOI
  41. Boyer W, 1995, Int Clin Psychopharmacol, 10, 45, 10.1097/00004850-199503000-00006 · DOI · Paper page
  42. Boyer W F., 1993, Int Clin Psychopharmacol, 8, 173, 10.1097/00004850-199300830-00006 · DOI
  43. Bradwejn J, 1993, Can J Psychiatry, 38, S109
  44. Brady K T., 1993, Psychiatr Q, 64, 135, 10.1007/BF01065866 · DOI
  45. Brady K, 2000, Jama, 283, 1837, 10.1001/jama.283.14.1837 · DOI · Paper page
  46. Braun P, 1990, J Clin Psychiatry, 51, 236
  47. Brom D, 1989, J Consult Clin Psychol, 57, 607, 10.1037/0022-006X.57.5.607 · doi:10.1037/0022-006x.57.5.607 · Paper page
  48. Bystritsky A, 1994, Anxiety, 1, 287, 10.1002/anxi.3070010608 · DOI
  49. Bystritsky A, 1999, Depress Anxiety, 10, 137, 10.1002/(SICI)1520-6394(1999)10:3<137::AID-DA8>3.0.CO;2-7 · doi:10.1002/(sici)1520-6394(1999)10:3<137::aid-da8>3.0.co;2-7
  50. Cahill S P., 1999, J Anxiety Disord, 13, 5, 10.1016/S0887-6185(98)00039-5 · DOI
  51. 10.3109/10401239909147053 · doi:10.3109/10401239909147053
  52. Cassano G B., 1988, J Affect Disord, 14, 123, 10.1016/0165-0327(88)90054-7 · DOI
  53. Charney D, 1999, Neurobiology of mental illness, 494
  54. Charney D S., 1989, J Clin Psychiatry, 50, 418
  55. Charney D S., 1986, J Clin Psychiatry, 47, 580
  56. Chouinard G, 1990, Psychopharmacol Bull, 26, 279
  57. Clark D M., 1995, Social phobia: Diagnosis, assessment, and treatment, 69
  58. Clomipramine Collaborative Study Group, 1991, Arch Gen Psychiatry, 48, 730, 10.1001/archpsyc.1991.01810320054008 · DOI · Paper page
  59. CNCPS, 1992, Br J Psychiat, 160, 191, 10.1192/bjp.160.2.191 · DOI · Paper page
  60. Cohen S D., 1984, Br J Psychiatry, 144, 276, 10.1192/bjp.144.3.276 · DOI
  61. Connor K M., 1998, Biol Psychiatry, 44, 1286, 10.1016/S0006-3223(98)00285-6 · DOI
  62. Connor K M., 1999, Br J Psychiatry, 175, 17, 10.1192/bjp.175.1.17 · DOI · Paper page
  63. Cottraux J, 1995, Br J Psychiatry, 167, 635, 10.1192/bjp.167.5.635 · DOI
  64. Cournoyer J, 1986, Can J Psychiatry, 31, 335, 10.1177/070674378603100410 · DOI
  65. Cowley D S., 1997, J Clin Psychiatry, 58, 555, 10.4088/JCP.v58n1208 · DOI
  66. Dannon P N., 2000, Eur Neuropsychopharmacol, 10, 165, 10.1016/S0924-977X(00)00065-1 · DOI
  67. Davidson J, 1990, Arch Gen Psychiatry, 47, 259, 10.1001/archpsyc.1990.01810150059010 · DOI · Paper page
  68. Davidson J RT, 1993, J Clin Psychopharmacol 1, 3, 423
  69. Davidson J R., 1998, J Clin Psychopharmacol, 18, 93, 10.1097/00004714-199802000-00020 · DOI
  70. Davidson J R., 1999, J Clin Psychiatry, 60, 528, 10.4088/JCP.v60n0805 · DOI · Paper page
  71. Davidson J, 2001, Am J Psychiatry, 158, 1974, 10.1176/appi.ajp.158.12.1974 · DOI · Paper page
  72. Davidson J R., 2001, Arch Gen Psychiatry, 58, 485, 10.1001/archpsyc.58.5.485 · DOI · Paper page
  73. DeMartinis N A., 1996, J Clin Psychiatry, 57, 245
  74. den Boer J A., 1990, Psychopharmacology Berl, 102, 85, 10.1007/BF02245749 · DOI · Paper page
  75. GeissDeVeaugh J, 1989, Psychopharmacol Bull, 25, 36
  76. De Veaugh‐Geiss J, 1992, J Am Acad Child Adolesc Psychiatry, 31, 45, 10.1097/00004583-199201000-00008 · DOI · Paper page
  77. Dunner D L., 1986, J Clin Psychiatry, 47, 458
  78. DuPont R L., 1996, Anxiety, 2, 167, 10.1002/(SICI)1522-7154(1996)2:4<167::AID-ANXI2>3.0.CO;2-L · DOI · Paper page
  79. Dyukova G M., 1992, Neurosci Behav Physiol, 22, 343, 10.1007/BF01182877 · DOI
  80. Elie R, 1984, J Clin Psychopharmacol, 4, 125, 10.1097/00004714-198406000-00002 · DOI
  81. Emslie C, 2000, Acta Psychiatrica Scandinavica, 101, 26, 10.1111/j.1600-0447.2000.tb10945.x · DOI
  82. Enkelmann R, 1991, Psychopharmacology, 105, 428, 10.1007/BF02244440 · DOI
  83. Ericson A, 1999, Eur J Clin Pharmacol, 55, 503, 10.1007/s002280050664 · DOI · Paper page
  84. Expert Consensus Panel for Obsessive‐Compulsive Disorder, 1997, J Clin Psychiatry, 58, 2
  85. Facorro B C., 1997, Actas Luso‐Españolas de Neurologia Psiquiatria y Ciencias Afines, 25, 61
  86. Fallon B A., 1998, Arch Gen Psychiatry, 55, 918, 10.1001/archpsyc.55.10.918 · DOI
  87. Feighner J P., 1982, J Clin Psychiatry, 43, 103
  88. Ferreri M, 1994, Encéphale, 20, 785
  89. Feske U, 1997, J Consult Clin Psychol, 65, 1026, 10.1037/0022-006X.65.6.1026 · doi:10.1037/0022-006x.65.6.1026
  90. Fesler F A, 1991, J Clin Psychiatry, 52, 361
  91. FitzGerald K D., 1999, J Child Adolesc Psychopharmacol, 9, 115, 10.1089/cap.1999.9.115 · DOI
  92. Foa E B, 2000, J Clin Psychiatry, 61, 43
  93. Fontaine R, 1983, J Clin Psychopharmacol, 3, 80, 10.1097/00004714-198304000-00005 · DOI
  94. Francobandiera G, 2001, Can J Psychiatry, 46, 356, 10.1177/070674370104600408 · DOI
  95. Frank J B., 1988, Am J Psychiatry, 145, 1289, 10.1176/ajp.145.10.1289 · DOI · Paper page
  96. Furukawa T A., Streiner D L., Young L T. 2002, Antidepressant and benzodiazepine for major depression (Cochrane Review) Cochrane Database Syst Rev CD001026 · DOI · Paper page
  97. Fux M, 1996, Am J Psychiatry, 153, 1219, 10.1176/ajp.153.9.1219 · DOI · Paper page
  98. Gelenberg A J., 2000, Jama, 283, 3082, 10.1001/jama.283.23.3082 · DOI · Paper page
  99. Geller D A., 2001, J Am Acad Child Adolesc Psychiatry, 40, 773, 10.1097/00004583-200107000-00011 · DOI · Paper page
  100. Goddard A W., 2001, Arch Gen Psychiatry, 58, 681, 10.1001/archpsyc.58.7.681 · DOI
  101. Goldstein A J., 2000, J Consult Clin Psychol, 68, 947, 10.1037/0022-006X.68.6.947 · DOI
  102. Goldstein D J., 1999, Hum Psychopharmacol Clin Exp, 14, 319, 10.1002/(SICI)1099-1077(199907)14:5<319::AID-HUP99>3.0.CO;2-D · DOI
  103. Goodman W K., 1989, Arch Gen Psychiatry, 46, 36, 10.1001/archpsyc.1989.01810010038006 · DOI · Paper page
  104. Goodman W K., 1996, Int Clin Psychopharmacol, 11, 21, 10.1097/00004850-199603000-00003 · DOI
  105. Gorman J M., 1987, J Clin Psychopharmacol, 7, 329, 10.1097/00004714-198710000-00007 · DOI · Paper page
  106. Gorman J M., 2000, Am J Psychiatry, 157, 493, 10.1176/appi.ajp.157.4.493 · DOI · Paper page
  107. Gould R A., 1993, Behav Ther, 24, 241, 10.1016/S0005-7894(05)80266-7 · DOI · Paper page
  108. Greist J H., 1998, Br J Psychiatry Suppl, 35, 64, 10.1192/S0007125000297912 · DOI
  109. Greist J, 1995, Arch Gen Psychiatry, 52, 289, 10.1001/archpsyc.1995.03950160039008 · DOI · Paper page
  110. Greist J H., 1995, Arch Gen Psychiatry, 52, 53, 10.1001/archpsyc.1995.03950130053006 · DOI · Paper page
  111. Hair T, 2000, Int J Neuropsychopharmacol, 3, S227
  112. Hamner M B., 1998, Int Clin Psychopharmacol, 13, 233, 10.1097/00004850-199809000-00008 · DOI
  113. Harvey A G., 1995, Psychiatr Clin North Am, 18, 859, 10.1016/S0193-953X(18)30027-3 · DOI
  114. Heimberg R G, 1995, Social Phobia—clinical and research perspectives, 293
  115. 10.1016/S0006-3223(99)00011-6 · DOI · Paper page
  116. Hertzberg M A., 2000, Ann Clin Psychiatry, 12, 101, 10.3109/10401230009147096 · DOI · Paper page
  117. Hoehn‐Saric R, 1988, J Clin Psychiatry, 49, 293
  118. 10.1097/00004714-199310000-00004 · DOI
  119. Hoehn‐Saric R, 2000, Arch Gen Psychiatry, 57, 76, 10.1001/archpsyc.57.1.76 · DOI
  120. Hoffart A, 1990, Psychotherapy, 27, 210, 10.1037/0033-3204.27.2.210 · DOI
  121. Hohagen F, 1998, Br J Psychiatry Suppl, 35, 71, 10.1192/S0007125000297924 · DOI · Paper page
  122. Hollon S, 1999, Psychotherapy Indications and Outcomes, 343
  123. IMCTGMSP, 1997, Eur Arch Psychiatry Clin Neurosci, 247, 71, 10.1007/BF02900196 · DOI
  124. Jacobson A F., 1985, Pharmacotherapy, 5, 290, 10.1002/j.1875-9114.1985.tb03430.x · DOI
  125. James I, 1984, Am Heart J, 108, 1150, 10.1016/0002-8703(84)90599-4 · DOI
  126. James I M., 1983, J R Soc Med, 76, 194, 10.1177/014107688307600308 · DOI
  127. Jenike M A., 1991, J Clin Psychiatry, 52, 13
  128. Jenike M A., 1997, Am J Psychiatry, 154, 1261, 10.1176/ajp.154.9.1261 · DOI
  129. Jetty P V., 2001, Psychiatr Clin North Am, 24, 75, 10.1016/S0193-953X(05)70207-0 · DOI
  130. Johnston D, 1988, Arch Gen Psychiat, 45, 453, 10.1001/archpsyc.1988.01800290073009 · DOI
  131. Kasper S, 2002, A placebo‐controlled study of pregabalin and venlafaxine treatment of GAD Poster
  132. Kasper S, 2002, Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. Poster
  133. Katz R J., 1990, Biol Psychiatry, 28, 401, 10.1016/0006-3223(90)90408-T · DOI · Paper page
  134. Katzelnick D J., 1995, Am J Psychiatry, 152, 1368, 10.1176/ajp.152.9.1368 · DOI · Paper page
  135. Kawahara T, 2000, Psychiatry Clin Neurosci, 54, 599, 10.1046/j.1440-1819.2000.00760.x · DOI
  136. Keck P E., 1993, Biol Psychiatry, 33, 542, 10.1016/0006-3223(93)90010-B · DOI
  137. Kessler R C., 1994, Arch Gen Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
  138. Klein D, 1964, Psychopharmacol, 5, 397, 10.1007/BF02193476 · DOI · Paper page
  139. Klein D F, 1998, Treatment, 1, 1
  140. Klein D F, 2000, Am J Psychiatry, 157, 1204, 10.1176/appi.ajp.157.8.1204 · DOI
  141. Klerman G L., 1991, Jama, 265, 742, 10.1001/jama.1991.03460060074027 · DOI · Paper page
  142. Klosko J S., 1990, J Consult Clin Psychol, 58, 77, 10.1037/0022-006X.58.1.77 · DOI · Paper page
  143. Kobak K A., 2002, J Clin Psychopharmacol, 22, 257, 10.1097/00004714-200206000-00005 · DOI
  144. Koran L M., 1997, Am J Psychiatry, 154, 396, 10.1176/ajp.154.3.396 · DOI
  145. Koran L M., 2000, J Clin Psychiatry, 61, 514, 10.4088/JCP.v61n0709 · DOI
  146. Kosten T R., 1991, J Nerv Ment Dis, 179, 366, 10.1097/00005053-199106000-00011 · DOI · Paper page
  147. Kronig M H., 1999, J Clin Psychopharmacol, 19, 172, 10.1097/00004714-199904000-00013 · DOI
  148. Krüger M B., 1999, Eur Archives Psychiatry Clin Neurosci, 249, S19, 10.1007/PL00014163 · DOI
  149. Lader M, 1998, Psychopharmacology‐Berl, 139, 402, 10.1007/s002130050731 · DOI
  150. Laegreid L, 1990, Dev Med Child Neural, 32, 432, 10.1111/j.1469-8749.1990.tb16962.x · DOI
  151. Lecrubier Y, 1997, Acta Psychiatr Scand, 95, 145, 10.1111/j.1600-0447.1997.tb00388.x · DOI
  152. Leonard H L., 1989, Arch Gen Psychiatry, 46, 1088, 10.1001/archpsyc.1989.01810120030006 · DOI · Paper page
  153. Leonard H L., 1994, J Am Acad Child Adolesc Psychiatry, 33, 792, 10.1097/00004583-199407000-00003 · DOI
  154. Lepola U, 1990, Human Psychopharmacol, 5, 159, 10.1002/hup.470050209 · DOI
  155. Lepola U M., 1998, J Clin Psychiatry, 59, 528, 10.4088/JCP.v59n1006 · DOI
  156. Li D, 2001, J Psychiatry Neurosci, 26, 190
  157. Lidren D M., 1994, J Consult Clin Psychol, 62, 865, 10.1037/0022-006X.62.4.865 · DOI · Paper page
  158. Liebowitz M R, 1987, Mod Probl Pharmacopsychiatry, 22, 141, 10.1159/000414022 · DOI · Paper page
  159. Liebowitz M R., 1988, J Clin Psychiatry, 49, 252
  160. Liebowitz M R., 1999, Depress Anxiety, 10, 89, 10.1002/(SICI)1520-6394(1999)10:3<89::AID-DA1>3.0.CO;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
  161. Lipper S, 1986, Psychosomatics, 27, 849, 10.1016/S0033-3182(86)72590-5 · DOI · Paper page
  162. Livingston M G, 1994, Br J Hosp Med, 51, 281
  163. Loerch B, 1999, Br J Psychiatry, 174, 205, 10.1192/bjp.174.3.205 · DOI
  164. Londborg P D., 1998, Br J Psychiatry, 173, 54, 10.1192/bjp.173.1.54 · DOI
  165. Londborg P D., 2001, J Clin Psychiatry, 62, 325, 10.4088/JCP.v62n0503 · DOI
  166. Lopez‐Ibor J J., 1996, Eur Neuropsychopharmacol, 6, 111, 10.1016/0924-977X(95)00071-V · DOI
  167. Lum M, 1990, Biol Psychiatry, 27, 164A
  168. Lydiard R B., 1992, J Clin Psychopharmacol, 12, 96, 10.1097/00004714-199204000-00004 · DOI
  169. Lydiard R B., 1997, J Clin Psychiatry, 58, 11, 10.4088/JCP.v58n1104 · DOI
  170. Mahe V, 2000, Int Clin Psychopharmacol, 15, 99, 10.1097/00004850-200015020-00006 · DOI
  171. Marazziti D, 1999, Am J Psychiatry, 156, 1834, 10.1176/ajp.156.11.1834-a · doi:10.1176/ajp.156.11.1834-a
  172. Marazziti D, 2001, Int Clin Psychopharmacol, 16, 215, 10.1097/00004850-200107000-00005 · DOI
  173. March J S., 1998, Jama, 280, 1752, 10.1001/jama.280.20.1752 · DOI · Paper page
  174. Markovitz P J., 1990, Am J Psychiatry, 147, 798, 10.1176/ajp.147.6.798 · DOI
  175. Marks I, 1994, Int Acad Biomed Drug Res, 8, 122
  176. Marks I M, 1987, Fears, phobias and rituals
  177. Marks I, 1983, Arch Gen Psychiat, 40, 153, 10.1001/archpsyc.1983.01790020047004 · DOI · Paper page
  178. Marmar C R., 1996, J Clin Psychiatry, 57, 66
  179. Marshall R D., 1998, J Clin Psychopharmacol, 18, 10, 10.1097/00004714-199802000-00003 · DOI
  180. Mavissakalian M, 1983, Psychopharmacol Bull, 19, 116
  181. Mavissakalian M, 1986, J Clin Psych, 47, 117
  182. Mavissakalian M, 1986, Am J Psych, 143, 1106, 10.1176/ajp.143.9.1106 · DOI
  183. Mavissakalian M, 1983, Br J Psychiatry, 143, 348, 10.1192/bjp.143.4.348 · DOI
  184. McDougle C J., 1991, J Clin Psychopharmacol, 11, 175, 10.1097/00004714-199106000-00005 · DOI
  185. McDougle C J., 1994, Arch Gen Psychiatry, 51, 302, 10.1001/archpsyc.1994.03950040046006 · DOI · Paper page
  186. 10.1176/ajp.155.11.1570 · DOI
  187. Michelson L, 1988, Behav Ther, 19, 97, 10.1016/S0005-7894(88)80035-2 · DOI
  188. Milanfranchi A, 1997, Int Clin Psychopharmacol, 12, 131, 10.1097/00004850-199705000-00002 · DOI
  189. Mindus P, 1994, J Neuropsychiatry Clin Neurosci, 6, 467, 10.1176/jnp.6.4.467 · DOI
  190. Misri S, 2000, Canadian Family Physician, 46, 626
  191. Misri S, 2000, Canadian Journal of Psychiatry‐Revue Canadienne De Psychiatrie, 45, 285, 10.1177/070674370004500309 · DOI
  192. Modigh K, 1992, J Clin Psychopharmacol, 12, 251, 10.1097/00004714-199208000-00007 · DOI
  193. Mohr N, 2002, Int Clin Psychopharmacol, 17, 37, 10.1097/00004850-200201000-00006 · DOI
  194. Möller H J., 2001, J Clin Psychopharmacol, 21, 59, 10.1097/00004714-200102000-00011 · DOI
  195. Montgomery S A., 1993, Eur Neuropsychopharmacol, 3, 143, 10.1016/0924-977X(93)90266-O · DOI · Paper page
  196. Montgomery S A., 2001, Int Clin Psychopharmacol, 16, 75, 10.1097/00004850-200103000-00002 · DOI · Paper page
  197. Moroz G, 1999, J Clin Psychiatry, 60, 604, 10.4088/JCP.v60n0907 · DOI
  198. Mundo E, 1998, Int Clin Psychopharmacol, 13, 219, 10.1097/00004850-199809000-00005 · DOI
  199. Mundo E, 2000, Int Clin Psychopharmacol, 15, 69, 10.1097/00004850-200015020-00002 · DOI
  200. Munjack D J., 1989, J Clin Psychopharmacol, 9, 22

200 of 316 shown

Cited by

See all 167

Metadata

Authors
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., & WFSBP Task Force on Treatment Guide
Venue
The World Journal of Biological Psychiatry
Published
2002-01
Volume
3
Issue
4
Pages
171-199
ISSN
  • 1562-2975 (ISSN-L)
  • 1814-1412
OpenAlex
W4205258863
Cited by
167
References
34
FWCI
15.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. https://app.cochat.ai/papers/10.3109/15622970209150621
The paper
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., & WFSBP Task Force on Treatment Guide. (2002). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. The World Journal of Biological Psychiatry. https://doi.org/10.3109/15622970209150621

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.